Intrinsyc Software International Inc.

ICS : TSX : C\$0.65

SPECULATIVE BUY

Target: C\$1.75

Peter Misek 1.416.869.792					
peter.misek@canaccordadams.cc	om				
Dushan Batrovic	1.416.869.7399				
dushan.batrovic@canaccordadam	ns.com				
Neal Gilmer	1.416.869.7294				
neal.gilmer@canaccordadams.com					

COMPANY STATISTICS:

52-week Range:	C\$0.34 - 0.77
Avg. Daily Vol. (000s):	154.4
Market Cap (M):	C\$77.5
Shares Out (M) basic:	119.3
Shares Out (M) diluted:	119.3

EARNINGS SUMMARY:

FYE Aug	2005A	2006A	2007A	2008E	2009E
Revenue (M):	17.5	18.7	19.7	29.7	69.1
EV/Sales (x):	3.3	3.1	2.9	2.0	0.8
EPS:	(0.11)	(0.24)	(0.18)	(0.10)	0.09
P/E (x):	NM	NM	NM	NM	7.1

SHARE PRICE PERFORMANCE:



COMPANY SUMMARY:

Intrinsyc Software is a mobility software and services company, based in Vancouver, BC. The company's technologies and services enable companies to identify and create solutions to make mobile devices connect and work. Intrinsyc creates and licenses mobile and embedded software products to OEMs, as well as a suite of server-based interoperability solutions. Additionally, the company provides engineering services to support these products.

All amounts in C\$ unless otherwise noted.

Technology -- Software -- Software and Services CONFIDENCE IN THE PIPELINE; ON TRACK FOR A STRONG 2008

Event

Intrinsyc reported Q4/F07 results in line with expectations. Revenue was posted at C\$4.5 million (down 8% Y/Y) versus our C\$4.6 million estimate and consensus of C\$4.4 million. The company's loss per share was one cent better than our estimates at (C\$0.03). Intrinsyc announced the intent to change its fiscal year end from August 31 to December 31 and to begin reporting in US currency.

Impact

We believe that Intrinsyc's Q4 results were solid but do not tell the whole story. The company is moving forward with its product development and is just beginning to realize value from its sizeable pipeline of prospects. While providing no guidance, management reaffirmed its goal of signing one Soleus deal per quarter, a target that we believe could prove to be conservative.

Action

Our estimates remain unchanged. Overall, we believe that Intrinsyc is making solid progress positioning itself in the high growth mobile OS market. In our view, Intrinsyc offers good stability with its engineering business and tremendous upside potential with the Soleus platform. Hence, we reiterate our SPECULATIVE BUY recommendation and C\$1.75 target price, based on our DCF analysis.

Valuation

Intrinsyc trades at a discount to peers on an F08 EV/Sales basis trading at 2.0 times, well below the industry average of 4.0 times. We believe the company should be trading at higher multiples than the peer average due to its impressive growth potential in F08 and beyond.

Canaccord Adams is the global capital markets group of Canaccord Capital Inc. (CCI : TSX|AIM)

The recommendations and opinions expressed in this Investment Research accurately reflect the Investment Analyst's personal, independent and objective views about any and all the Designated Investments and Relevant Issuers discussed herein. For important information, please see the Important Disclosures section in the appendix of this document or visit http://www.canaccordadams.com/research/Disclosure.htm.

Q4/F07 results

Intrinsyc reported Q4/F07 results in line with expectations. Revenue was posted at C\$4.5 million (down 8% Y/Y) versus our C\$4.6 million estimate and consensus of C\$4.4 million. The company's loss per share was one cent better than our estimates at (C\$0.03). Intrinsyc burned C\$3.3 million in free cash, ending the quarter with C\$19.6 million or C\$0.16 per share in cash and equivalents. Services revenue declined slightly Q/Q from C\$4.3 million to C\$4.0 million. Software increased from C\$0.5 million to C\$0.6 million in the same time frame. Gross margins fell 270 basis points sequentially; however improved 240 basis points on a Y/Y basis. Foreign exchange negatively impacted the top line growth rate about 4% on a Y/Y basis.

Figure 1: Q4/F07 results

(C\$ millions)	Q4/F07A	CA Q4/F07E	B/(W)	Q3/F07A	Q4/F06A	Consensus	% Change Q/Q	% Change Y/Y
Revenue	4.5	4.6	-0.0	5.1	4.9	4.4	-11.3%	-7.9%
Gross Profit	2.2	2.3	-0.0	2.6	2.3		-15.9%	-3.2%
% of Revenue	49.1%	49.6%		51.8%	46.7%			
Total Op Ex	6.4	7.0	-0.6	6.6	6.5		-2.1%	-0.9%
% of Revenue	141.4%	153.9%		128.3%	131.5%			
EBITDA	-4.0	-4.5	0.6	-3.7	-4.0		NA	NA
% of Revenue	-87.4%	-99.8%	0.0	-72.5%	-80.9%			
GAAP Net Income	-4.1	-4.6	0.5	-4.4	-4.4		NA	NA
% of Revenue	-90.6%	-101.3%		-85.7%				
GAAP EPS - diluted	(0.03)	(0.04)		(0.05)	(0.05)		NA	NA
Adjusted EPS - diluted	(0.03)	(0.04)	0.0	(0.04)	(0.05)	(0.04)	NA	NA

Source: Canaccord Adams, Company reports, Bloomberg

Soleus Update

Intrinsyc released Soleus version 1.01 in August 2007. Key advancements to the product include language localization and the ability to automatically switch between languages, user interface improvements and the ability to migrate to Windows Mobile 6.0. Management noted that future R&D would be focused on developing a 3G version of the product. As well, the company is looking at movement and gesture-based user interfaces.

The company noted that services revenue contributed 84% in Q4/F07, compared to 88% last quarter. Software revenue was up from 10% last quarter to 13%, with Soleus contributing C\$81,000 of this total. This is the first time management has disclosed the Soleus figure – this is one we will clearly be keeping our eyes on in the future. Q4 Soleus revenue only includes upfront license and maintenance revenue. No royalties are expected until the first half of 2008. Soleus related R&D and S&M were C\$2.9 million in Q4/F07.

After two quarters of significant sequential declines, we expect this figure to stabilize in the C\$3 million range for the next few quarters.

Figure 1: Soleus expense analy	sis						
(C\$ '000)	28-Feb-06	31-May-06	31-Aug-06	30-Nov-06	28-Feb-07	31-May-07	31-Aug-07
Soleus related R&D and S&M	2,510	2,930	3,580	3,370	3,800	3,300	2,900
Sequential Growth	63.0%	16.7%	22.2%	-5.9%	12.8%	-13.2%	-12.1%
as % of revenue	52.4%	66.8%	72.7%	67.1%	75.5%	64.6%	63.9%

Source: Company reports, Canaccord Adams

Google Android

When asked about Google's new Android announcement, management responded that it was encouraged by the initiative. We continue to believe that the Open Handset Alliance's (OHA) focus on the mass feature phone segment validates the track that Intrinsyc has been on with Soleus. Given the complexity of building an ecosystem with 30+ members, management believes that developing a production-ready product will be a time-consuming process. As the mass market appears ready for higher multimedia applications today, we do not anticipate that OEMs and ODMs will wait indefinitely. As a result, we like Intrinsyc's chances of securing a position of critical mass with several customers before Android comes to market. Additionally, management noted that it is in the process of adapting Soleus to Linux-based environments. We believe this could result in Intrinsyc eventually joining the OHA as well.

PND Market

We believe that Personal Navigation Device (PND) makers will be looking to add more wireless/telephony capabilities to their devices throughout 2008. This in our view will be driven by device vendors' need to both capture map data in real time and to eventually distribute map updates wirelessly. For more detail on trends in the PND and broader location technologies markets, please refer to research from Canaccord Adams' technology analyst, Jeff Rath. We believe that Intrinsyc is in a position to benefit from the convergence of GPS-centric devices and mobile handsets. To date, all three of the company's Soleus design wins have originated from GPS-enabled devices. We expect the activity in this segment to accelerate, particularly heading into 3GSM and CeBIT early next year.

Pipeline Update

Management remains consistent in its pipeline commentary. The company sees about 30 unique customers, representing approximately 100 million annual units as the immediately addressable market opportunity. Management remains committed to signing about 1 Soleus deal per quarter. Given the pipeline activity we are witnessing, we believe this goal could prove to be conservative.

Intrinsyc elaborated upon an additional opportunity around silicon and chip makers. We had considered this market as a secondary prospect; however management's enthusiastic tone would seem to suggest that the potential is closer than we had initially assumed. The concept here is silicon makers bundling the software with their hardware in order to offer

a full turnkey solution to service providers. Management referred to a market size representing a few hundred million units per year.

Cash and cash flow

Intrinsyc recorded free cash flow in the quarter of (C\$3.5) million, compared to (C\$2.8) million in Q3/F07 and (C\$3.9) million in Q4/F07. Cash balances at the end of the quarter totaled C\$19.6 million, down from C\$21.4 million the previous quarter and C\$22.5 million Y/Y. Accounts receivables equaled C\$3.1 million for the quarter, up C\$0.1 million Q/Q and down \$0.7 million Y/Y. Finally, prepaid expenses were C\$0.5 million for the quarter, up over C\$0.2 million sequentially and up C\$0.2 million from the prior year.

Costs and margins

Gross margin in the quarter was 49%, down slightly from last quarter at 51% but up over Q4/F06 at 47%. Operating expenses were C\$6.4 million for the quarter compared to our estimate of C\$7.0 million and down slightly from Q3/F07. This was a result of reduced R&D expenses and G&A expenses of C\$2.8 million and C\$1.3 million respectively, offset by slightly higher S&M expenses of C\$1.8 million.

Estimate revisions

Intrinsyc announced two financial reporting changes that have been approved by the company's Board of Directors. Firstly, the company intends to change its fiscal year end from August 31 to December 31, effective January 1, 2008. The company stated that this change will better align with the business cycle with that of its customers. Intrinsyc intends to report a stub period of September 1 – December 31, 2007 in March of 2008. Secondly, Intrinsyc intends to begin reporting financials in U.S. currency given that the majority of sales are recorded in US dollars. Intrinsyc is currently in the process of obtaining the necessary approvals from the TSX and Revenue Canada and expects approval before year end.

Intrinsyc also announced that it is considering closing its UK engineering services operation. The company is engaged in a consultation process, which should be completed over the next four weeks. If Intrinsyc proceeds with the closure, the company expects to incur a C\$0.8 million charge in the current quarter. Management estimates the savings from the closure to be approximately C\$2.0 million annually with minimal impact to revenues as it expects to absorb the engineering workload through other offices.

We have kept our estimates unchanged at this time, pending the completion of the consultation process and approval of the financial changes. For Q1/F08 our revenue estimate is C\$5.2 million with EPS at (C\$0.03). For F08, we project revenues of C\$29.7 million and EPS of (C\$0.10). In F09, we are at C\$69.1 million and C\$0.09.

Outlook and recommendation

We believe that Intrinsyc's Q4 results were solid but do not tell the whole story. The company is moving forward with its product development and is just beginning to realize value from its sizeable pipeline of prospects. While providing no guidance, management re-affirmed its goal of signing one Soleus deal per quarter, a target that we believe could prove to be conservative. We expect Intrinsyc to release its 3G platform in early 2008, which could spark a few more large customers within the active pipeline of roughly 30 to engage Soleus. We believe that the PND market will continue to migrate towards

wireless/telephony-enabled solutions, which should benefit Intrinsyc as a facilitator of that convergence. With three Soleus wins to date and several more on the way in our view, we continue to expect a significant sales ramp in the back half of 2008.

Overall, we believe that Intrinsyc is making solid progress positioning itself in the high growth mobile OS market. In our view, Intrinsyc offers good stability with its engineering business and tremendous upside potential with the Soleus platform. Hence, we reiterate our SPECULATIVE BUY recommendation and C\$1.75 target price, based on our DCF analysis.

Valuation

Intrinsyc trades at a discount to peers on an F08 EV/Sales basis trading at 2.0 times, well below the industry average of 4.0 times. We believe the company should be trading at higher multiples than the peer average due to its impressive growth potential in F08 and beyond.

Figure 2: Comparables

				Revenue			EPS		EV/S	Sales	P/	/E	
			LAST	F07	F08	Growth	F07	F08	Growth	F07	F08	F07	F08
Access	4813	: TSE	434,000	26,212	32,787	25%	-40,982	-40,025	-2%	6.5	5.2	NM	NM
Aplix	3727	: TSE	257,000	6,128	6,639	8%	-78,467	6,001	NM	4.2	3.9	NM	42.8
Trolltech	TROLL	: 0S	11.20	229.5	312.0	36%	-0.60	-0.16	NM	1.9	1.4	NM	NM
Call Genie	GNE.	:V	\$1.08	2.3	12.6	NM	-0.13	-0.08	NM	NM	5.0	NM	NM
Red Hat	RHT	:N	\$21.00	488.0	608.0	25%	0.66	0.83	26%	7.8	6.2	31.8	25.3
Research In Motion	RIMM	:Q	\$124.38	4,222.0	7,650.0	81%	1.54	3.07	99%	16.2	8.9	80.8	40.5
Wind River	WIND	:Q	\$11.74	328	371	13%	0.30	0.49	63%	2.8	2.4	39.1	24.0
Zamano	ZMNO	:L	0.33	21	25	23%	0.04	0.05	20%	0.7	0.6	0.1	0.1
Zi Corp.	ZICA	:Q	\$1.04	13	15	19%	-0.11	-0.04	NM	3.2	2.7	NM	NM
Average						29%			41%	5.4	4.0	38.0	26.5
Median						24%			26%	3.7	3.9	35.5	25.3
Intrinsyc	ICS.	:Т	\$0.65	20	30	51%	-0.17	-0.10	70%	2.9	2.0	NM	NM
Intrinsyc	ICS.	:T	\$1.75	20	30	51%	-0.17	-0.10	70%	9.6	6.4	NM	NM

Source: Canaccord Adams estimates, Bloomberg, Company reports

Investment risks

The main risks to our outlook include the competitive environment intensifying, design wins take longer than expected to close, design wins to not translate into material revenue due to failed device launches, ESG division revenue erosion, and key management leaving the firm. Other risks include litigation, adverse F/X trends, slower-than-expected growth in the mobile device market, faster-than-expected ASP erosion at handset OEM/ODMs pressuring Intrinsyc's ASPs down significantly, and broader macroeconomic forces impacting the market.

APPENDIX: IMPORTANT DISCLOSURES Analyst Certification: Each author

Each authoring analyst of Canaccord Adams whose name appears on the front page of this investment research hereby certifies that (i) the recommendations and opinions expressed in this investment research accurately reflect the authoring analyst's personal, independent and objective views about any and all of the designated investments or relevant issuers discussed herein that are within such authoring analyst's coverage universe and (ii) no part of the authoring analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the authoring analyst in the investment research.

Site Visit:

An analyst has visited Intrinsyc's material operations in Vancouver, BC, Canada. No payment or reimbursement was received from the issuer for the related travel costs.

Price Chart:*



* Price charts assume event 1 indicates initiation of coverage or the beginning of the measurement period.

Rating # % % Buy 301 57.6% 42.5% Speculative Buy 55 10.5% 69.1% Hold 149 28.5% 30.9% Sell 18 3.4% 5.6% 523 100.0% 523 100.0% Canaccord Ratings BUY: The stock is expected to generate risk-adjusted ret HOLD: The stock is expected to generate risk-adjusted ret System: BUY: The stock is expected to generate risk-adjusted ret SELL: The stock is expected to generate risk-adjusted ret NOT RATED: Canaccord Adams does not provide resear "Risk-adjusted return" refers to the expected return in r designated investment or the relevant issuer. SPECULATIVE: Stocks bear significantly higher risk that Canaccord Adams Research Disclosures as of 9 November 2007 Company
Speculative Buy5510.5%69.1%Hold14928.5%30.9%Sell183.4%5.6%523100.0%BUY: The stock is expected to generate risk-adjusted retHOLD: The stock is expected to generate risk-adjusted retHOLD: The stock is expected to generate risk-adjusted retNOT RATED: Canaccord Adams does not provide resear"Risk-adjusted return" refers to the expected return in rdesignated investment or the relevant issuer.Risk Qualifier:SPECULATIVE: Stocks bear significantly higher risk that criteria. Investments in the stock may result in materialCanaccord Adams Research Disclosures as of 9 November 2007
Hold 149 28.5% 30.9% Sell 18 3.4% 5.6% 523 100.0% Canaccord Ratings BUY: The stock is expected to generate risk-adjusted ret HOLD: The stock is expected to generate risk-adjusted ret SELL: The stock is expected to generate negative risk-ad NOT RATED: Canaccord Adams does not provide resear "Risk-adjusted return" refers to the expected return in r designated investment or the relevant issuer. Risk Qualifier: SPECULATIVE: Stocks bear significantly higher risk tha criteria. Investments in the stock may result in material Canaccord Adams Research Disclosures as of 9 November 2007
523 100.0% Canaccord Ratings BUY: The stock is expected to generate risk-adjusted ret System: HOLD: The stock is expected to generate risk-adjusted ret System: SELL: The stock is expected to generate negative risk-adjusted ret NOT RATED: Canaccord Adams does not provide resear "Risk-adjusted return" refers to the expected return in r designated investment or the relevant issuer. Risk Qualifier: SPECULATIVE: Stocks bear significantly higher risk that criteria. Investments in the stock may result in material Canaccord Adams Research Disclosures as of 9 November 2007
Canaccord Ratings System:BUY: The stock is expected to generate risk-adjusted ret HOLD: The stock is expected to generate risk-adjusted ret SELL: The stock is expected to generate negative risk-adjusted resear "SELL: The stock is expected to generate negative risk-adjusted return" refers to the expected return in r designated investment or the relevant issuer.Risk Qualifier:SPECULATIVE: Stocks bear significantly higher risk that criteria. Investments in the stock may result in materialCanaccord Adams Research Disclosures as of 9 November 2007
System: HOLD: The stock is expected to generate risk-adjusted resear SELL: The stock is expected to generate negative risk-adjusted resear NOT RATED: Canaccord Adams does not provide resear "Risk-adjusted return" refers to the expected return in redesignated investment or the relevant issuer. SPECULATIVE: Stocks bear significantly higher risk that criteria. Investments in the stock may result in material Canaccord Adams Research Disclosures as of 9 November 2007
Company
Intrinsyc Software International Inc.
munisyc Sonware international nic.

to the relevant issuer: A. investment banking services.

B. non-investment banking securities-related services.

C. non-securities related services.

9 November 2007

2 In the past 12 months, Canaccord Adams or its affiliated companies have received compensation for Corporate Finance/Investment Banking services from the relevant issuer.

3 In the past 12 months, Canaccord Adams or any of its affiliated companies have been lead manager, co-lead manager or co-manager of a public offering of securities of the relevant issuer or any publicly disclosed offer of securities of the relevant issuer or in any related derivatives.

- **4** Canaccord Adams acts as corporate broker for the relevant issuer and/or Canaccord Adams or any of its affiliated companies may have an agreement with the relevant issuer relating to the provision of Corporate Finance/Investment Banking services.
- **5** Canaccord Adams or any of its affiliated companies is a market maker or liquidity provider in the securities of the relevant issuer or in any related derivatives.
- **6** In the past 12 months, Canaccord Adams, its partners, affiliated companies, officers or directors, or any authoring analyst involved in the preparation of this investment research has provided services to the relevant issuer for remuneration, other than normal course investment advisory or trade execution services.
- 7 Canaccord Adams intends to seek or expects to receive compensation for Corporate Finance/Investment Banking services from the relevant issuer in the next six months.
- **8** The authoring analyst, a member of the authoring analyst's household, or any individual directly involved in the preparation of this investment research, has a long position in the shares or derivatives, or has any other financial interest in the relevant issuer, the value of which increases as the value of the underlying equity increases.
- **9** The authoring analyst, a member of the authoring analyst's household, or any individual directly involved in the preparation of this investment research, has a short position in the shares or derivatives, or has any other financial interest in the relevant issuer, the value of which increases as the value of the underlying equity decreases.
- **10** Those persons identified as the author(s) of this investment research, or any individual involved in the preparation of this investment research, have purchased/received shares in the relevant issuer prior to a public offering of those shares, and such person's name and details are disclosed above.
- **11** A partner, director, officer, employee or agent of Canaccord Adams and its affiliated companies, or a member of his/her household, is an officer, or director, or serves as an advisor or board member of the relevant issuer and/or one of its subsidiaries, and such person's name is disclosed above.
- **12** As of the month end immediately preceding the date of publication of this investment research, or the prior month end if publication is within 10 days following a month end, Canaccord Adams or its affiliate companies, in the aggregate, beneficially owned 1% or more of any class of the total issued share capital or other common equity securities of the relevant issuer or held any other financial interests in the relevant issuer which are significant in relation to the investment research (as disclosed above).
- **13** As of the month end immediately preceding the date of publication of this investment research, or the prior month end if publication is within 10 days following a month end, the relevant issuer owned 1% or more of any class of the total issued share capital in Canaccord Adams or any of its affiliated companies.
- **14** Other specific disclosures as described above.

Canaccord Adams is the business name used by certain subsidiaries of Canaccord Capital Inc., including Canaccord Adams Inc., Canaccord Adams Limited, and Canaccord Adams, a division of Canaccord Capital Corporation. Clients of Canaccord Adams, in the past 12 months, may have been clients of Canaccord Capital Corporation, Canaccord Capital (Europe) Limited, Canaccord Capital Corporation USA Inc., and/or Adams Harkness Financial Group Ltd.

The authoring analysts who are responsible for the preparation of this investment research are employed by Canaccord Adams, a securities broker-dealer with principal offices located in Vancouver, Calgary, Toronto, Montreal (all Canada), Boston, New York, San Francisco (all US) and London (UK).

In the event that this is compendium investment research (covering six or more relevant issuers), Canaccord Adams and its affiliated companies may choose to provide specific disclosures of the subject companies by reference, as well as its policies and procedures regarding the dissemination of investment research. To access this material or for more information, please send a request to Canaccord Adams Research, Attn: Disclosures, P.O. Box 10337 Pacific Centre, 2200-609 Granville Street, Vancouver, BC, Canada V7Y 1H2 or disclosures@canaccordadams.com.

The authoring analysts who are responsible for the preparation of this investment research have received (or will receive) compensation based upon (among other factors) the Corporate Finance/Investment Banking revenues and general profits of Canaccord Adams. However, such authoring analysts have not received, and will not receive, compensation that is directly based upon or linked to one or more specific Corporate Finance/Investment Banking activities, or to recommendations contained in the investment research. Canaccord Adams and its affiliated companies may have a Corporate Finance/Investment Banking or other relationship with the company that is the subject of this investment research and may trade in any of the designated investments mentioned herein either for their own account or the accounts of their customers, in good faith or in the normal course of market making. Accordingly, Canaccord Adams or their affiliated

	companies, principals or employees (other than the authoring analyst(s) who prepared this investment research) may at any time have a long or short position in any such designated investments, Related designated investments or in options, futures or other derivative instruments based thereon. Some regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. This investment research has been prepared in accordance with Canaccord Adams' policy on managing conflicts of interest, and information barriers or firewalls have been used where appropriate. Canaccord Adams' policy is available upon request.
	The information contained in this investment research has been compiled by Canaccord Adams from sources believed to be reliable, but (with the exception of the information about Canaccord Adams) no representation or warranty, express or implied, is made by Canaccord Adams, its affiliated companies or any other person as to its fairness, accuracy, completeness or correctness. Canaccord Adams has not independently verified the facts, assumptions, and estimates contained herein. All estimates, opinions and other information contained in this investment research constitute Canaccord Adams' judgement as of the date of this investment research, are subject to change without notice and are provided in good faith but without legal responsibility or liability.
	Canaccord Adams salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and our proprietary trading desk that reflect opinions that are contrary to the opinions expressed in this investment research. Canaccord Adams' affiliates, proprietary trading desk, and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this investment research.
	This investment research is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any designated investments discussed herein in any jurisdiction where such offer or solicitation would be prohibited. As a result, the designated investments discussed in this investment research may not be eligible for sale in some jurisdictions. This investment research is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. This material is prepared for general circulation to clients and does not have regard to the investment objectives, financial situation or particular needs of any particular person. Investors should obtain advice based on their own individual circumstances before making an investment decision. To the fullest extent permitted by law, none of Canaccord Adams, its affiliated companies or any other person accepts any liability whatsoever for any direct or consequential loss arising from or relating to any use of the information contained in this investment research.
For Canadian Residents:	This Investment Research has been approved by Canaccord Adams, a division of Canaccord Capital Corporation, which accepts responsibility for this Investment Research and its dissemination in Canada. Canadian clients wishing to effect transactions in any Designated Investment discussed should do so through a qualified salesperson of Canaccord Adams, a division of Canaccord Capital Corporation in their particular jurisdiction.
For United Kingdom Residents:	This Investment Research complies with of the Financial Services Authority's Handbook's chapter on Conduct of Business and is approved by Canaccord Adams Limited, which is regulated and authorized by the Financial Services Authority, in connection with its distribution in the United Kingdom. This material is not for distribution in the United Kingdom to private customers, as defined under the rules of the Financial Services Authority. Canaccord Adams Limited accepts responsibility for this Investment Research and its dissemination in the United Kingdom. The information contained in this Investment Research is only intended for distribution in the UK to persons who qualify as intermediate customers or market counterparties, as defined under the rules of the Financial Services Authority.
For United States Residents:	Canaccord Adams Inc., a US registered broker-dealer, accepts responsibility for this Investment Research and its dissemination in the United States. This Investment Research is intended for distribution in the United States only to certain US institutional investors. US clients wishing to effect transactions in any Designated Investment discussed should do so through a qualified salesperson of Canaccord Adams Inc.
For European Residents:	If this Investment Research is intended for disclosure in any jurisdiction other than the United Kingdom, the US or Canada, then the relevant rules and regulatory requirements of that jurisdiction will apply.
	Additional information is available on request. Copyright © Canaccord Adams, a division of Canaccord Capital Corporation 2007. – Member IDA/CIPF Copyright © Canaccord Adams Limited 2007. – Member LSE, regulated and authorized by the Financial Services Authority. Copyright © Canaccord Adams Inc. 2007. – Member FINRA/SIPC All rights reserved. All material presented in this document, unless specifically indicated otherwise, is under copyright to Canaccord Adams, a division of Canaccord Capital Corporation, Canaccord Adams Limited, and Canaccord Adams Inc. None of the material, nor its content, nor any copy of it, may be altered in any way, or

Daily Letter | 9

9 November 2007

transmitted to or distributed to any other party, without the prior express written permission of the entities listed above.